Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2026 | How do biomarkers of AD differ among diverse populations?

Sid O’Bryant • 20 Mar 2026
AD/PD 2026
Alzheimer’s Disease Dementia
HABS-HD

Sid O’Bryant, PhD, Institute for Translational Research at UNT Health, Fort Worth, TX, shares insights from the HABS-HD study into differences in biomarkers of Alzheimer’s disease (AD) among diverse populations. Dr O’Bryant notes that the sequence of biomarker progression differs among groups. This interview took place at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sid O’Bryant

Representation of diverse populations in AD research
2:08
Representation of diverse populations in AD research
Sid O’Bryant • 20 Mar 2026
The Health & Aging Brain Study: understanding brain health and aging to achieve precision medicine
2:56
The Health & Aging Brain Study: understanding brain health and aging to achieve precision medicine
Sid O’Bryant • 10 Dec 2025
Barriers and strategies to ensure equitable participation in Alzheimer’s disease clinical trials
2:48
Barriers and strategies to ensure equitable participation in Alzheimer’s disease clinical trials
Sid O’Bryant • 10 Dec 2025
Integrating advancements in blood biomarkers for neurodegenerative diseases into primary care
3:24
Integrating advancements in blood biomarkers for neurodegenerative diseases into primary care
Sid O’Bryant • 10 Dec 2025

Related Videos

Representation of diverse populations in AD research
2:08
Representation of diverse populations in AD research
Sid O’Bryant • 20 Mar 2026
Community perspectives on epigenetic dementia risk testing
2:49
Community perspectives on epigenetic dementia risk testing
James Galvin • 10 Mar 2026
Mechanisms of cognitive resilience and brain health
5:40
Mechanisms of cognitive resilience and brain health
James Galvin • 10 Mar 2026
Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB
6:06
Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB
James Galvin • 10 Mar 2026
The content of VJDementia is intended for healthcare professionals